| Literature DB >> 29511526 |
Fatema Alzahraa Almohamad1, Tareq Ahmad1, Basel Ahmad1, Khalid Hussain2, Lama Hadid3, Majdi Zein4, Mohamad Ahmad5.
Abstract
Iodine has always been connected to thyroid gland, and the fact that thyroid tissue traps, organificates and stores iodine more than other tissues is well known, hence the use of radioiodine as a diagnostic and therapeutic tool for thyroid disorders. However, false-positive cases do occur. We present a case of a 34-year-old patient who underwent total thyroidectomy for papillary carcinoma. Results of follow up TSH, thyroglobulin and thyroglobulin antibody tests after surgery lead to two rounds of radioactive iodine. After that, a radioiodine whole-body scan showed high uptake in the pelvis above bladder. Computed tomography scan showed a pelvic heterogeneous mass with some calcifications. Surgical removal and subsequent pathology confirmed the absence of metastasis. The final pathological diagnosis was serous cystadenoma, endometriosis cyst and leiomyoma. As the real cause behind false-positive iodine uptake by these tissues has yet to be determined, careful assessment should be considered in any suspicious case.Entities:
Year: 2018 PMID: 29511526 PMCID: PMC5829570 DOI: 10.1093/jscr/rjy028
Source DB: PubMed Journal: J Surg Case Rep ISSN: 2042-8812
Figure 1:Radioiodine WBS.
Lab results on admission.
| Test | Result | Reference range |
|---|---|---|
| White blood cells | 6800/ μl | 4400–11 000/ μl |
| Neutrophils percent | 78% | 40–70% |
| Hemoglobin | 10.9 g/dl | 13–16 g/dl |
| Hematocrit | 32.7% | 38–53% |
| Platelets | 205 × 103/ μl | 150–450 × 103/ μl |
| Urea | 18 mg/dl | 10–50 mg/dl |
| Creatinin | 0.5 mg/dl | 0.7–1.36 mg/dl |
| ALT | 11 IU/l | 8–20 IU/l |
| AST | 17 IU/l | 8–20 IU/l |
| PT | 83% | |
| CEA | 0.8 | |
| CA19_9 | 22.7 | |
| CA125 | 18.3 | |
| TSH | 3.4 uIU/ml | 0.4–4 uIU/ml |
| Ft4 | 1.6 |
Figure 2:CT scan.
Figure 3:Pathology.
Thyroid function results.
| TSH | Thyroglobulin | Thyroglobulin antibody | |
|---|---|---|---|
| Before first radioiodine dose | 52 uIU/ml (0.4–4 uIU/ml) | >500 ng/ml (1.7–55.6 ng/ml) | 16.1 uIU/ ml (0–40 uIU/ml) |
| After first dose (3 months) | 0.1 uIU/ml (0.4–4 uIU/ml) | >500 ng/ml (1.7–55.6 ng/ml) | 18.1 uIU/ ml (0–40 uIU/ ml) |
| Before second dose (6 months) | 16.4 uIU/ml (0.4–4 uIU/ml) | >500 ng/ml (1.7–55.6 ng/ml) | |
| After second dose and surgery (9 months) | 0.45 uIU/ml (0.4–4 uIU/ml) | <0.2 ng/ml (1.7–55.6 ng/ml) | 27 uIU/ml (0–40 uIU/ml) |